Results 51 to 60 of about 17,995 (265)

Atezolizumab‐induced pure red cell aplasia

British Journal of Haematology, 2021
A 45-year-old woman underwent a bone marrow biopsy for evaluation of persistent, severe transfusion-dependent normocytic anaemia, beginning approximately two months following initiation of olaparib and atezolizumab therapy for a metastatic BRCA1-mutated ...
R. Bennett, A. Ruskova
semanticscholar   +1 more source

Remission of pure red cell aplasia following oxymetholone therapy [PDF]

, 1978
A 53-year-old male with a long-standing idiopathic pure red cell aplasia, refractory to testosterone cypionate, fluoxymesterone, and corticosteroid, was successfully treated with oxymetholone.
Chang, Jae C, Lindsay, Naomi, Slutzker, Berkeley   +2 more
core   +1 more source

Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. [PDF]

, 2002
In part A of this study, patients were randomised to cohorts receiving darbepoetin alfa at doses of 0.5 to 8.0 m.c.g x kg(-1) x wk(-1) or to a control group receiving epoetin alfa at an initial dose of 150 U x kg(-1) three times weekly.
Armstrong, S, Colowick, AB, Glaspy, JA, Jadeja, JS, Justice, G, Kessler, J, O'Byrne, J, Richards, D, Rossi, G, Schwartzberg, L, Tchekmedyian, NS   +10 more
core   +2 more sources

The Evolving Landscape of Immunotoxicity: Charting Mechanisms and Future Strategies for Immune Checkpoint Inhibitor Adverse Events

Med Research, EarlyView.
ABSTRACT The use of immune checkpoint inhibitors (ICIs) has significantly improved the efficacy of cancer therapy, but their associated immune‐related adverse events (irAEs) can severely compromise treatment safety. This review systematically summarizes the core mechanisms underlying irAEs, which include multi‐organ damage resulting from T‐cell ...
Anqi Lin, Keyin Zheng, Aimin Jiang, Xufeng Huang, Qi Wang, András Hajdu, Zhengrui Li, Jian Zhang, Peng Luo   +8 more
wiley   +1 more source

PURE RED CELL APLASIA INDUCED BY ERYTHROPOIETIN

Sanamed, 2018
Introduction: Recombined human erythropoietin has been present in clinical practice for more than 20 years, in these therapeutic indications: anemia in kidney insufficiency, anemia during chemotherapy of tumors, prevention of anemias that appear in ...
MIhajlovic Filip, Milosavljevic Aleksandar, Djuric Dusan   +2 more
doaj   +1 more source

Autoimmune Cytopenias Developing Late Post Alemtuzumab-Based Allogeneic Stem Cell Transplantation: Presentation of Short Case Series from a Transplant Center

Cell Transplantation, 2020
Stem cell transplantation remains the curative option for many patients with hematological malignancies. The long-term effects of these treatments on the patients and their immune systems have been extensively investigated, but there remains a paucity of
Rebecca Lloyd, Emmanouil Nikolousis, Bhuvan Kishore, Richard Lovell, Paneesha Shankara, Nervana Abou Zeid, Claire Horgan, Alkistis Kyra Panteliadou, Graham McIlroy, Evgenia Xenou, Maria Kaparou, Kathleen Holder, Vidhya Murthy, Alexandros Kanellopoulos   +13 more
doaj   +1 more source

Acquired pure red cell aplasia: unraveling the immune pathogenesis

Journal of Bio-X Research, 2023
Acquired pure red cell aplasia (aPRCA) is a rare hematological disorder characterized by normochromic, normocytic anemia, reticulocytopenia, and the absence of erythroblasts. The pathogenesis of aPRCA has remained elusive.
Mengyuan Liu, Tian Zhang, Xifeng Dong, Huaquan Wang   +3 more
doaj   +1 more source

Isoniazid Induced Pure Red Blood Cell Aplasia

Cureus, 2020
Pure red blood cell aplasia (PRCA) is one of the uncommon causes of anemia. Drug-induced PRCA is even more infrequent. Only a few drugs are implicated in PRCA. Isoniazid is a widely used drug for the treatment of tuberculosis all over the world.
Waqas Azhar, F. Zaidi, A. Hannan
semanticscholar   +1 more source

Pure red-cell aplasia associated with carbamazepine: A case report [PDF]

, 2017
A 3-year-old girl developed pure red-cell aplasia while being treated with carbamazepine for a seizure disorder. Spontaneous recovery took place after discontinuation of the drug.
Buitendag, D.J.
core   +1 more source

Drug Candidate BIO101 for Spinal Muscular Atrophy as Monotherapy or Combined With the Antisense Oligonucleotide ASO‐10‐27

Journal of Cachexia, Sarcopenia and Muscle, Volume 16, Issue 5, October 2025.
ABSTRACT Background Spinal muscular atrophy (SMA) is a neuromuscular disease caused by loss of survival of motor neuron (SMN) protein inducing progressive muscle weakness and atrophy due to motor neurons degeneration. Despite benefits of SMN restoration therapies in patients, motor defects are still persistent.
Cynthia Bézier, Steve Cottin, Parvin Nazari Hashemi, Mirella El Khoury, Zoé Clerc, Christine Balducci, Delphine Sapaly, Laure Weill, René Lafont, Stanislas Veillet, Pierre J. Dilda, Frédéric Charbonnier, Mathilde Latil, Olivier Biondi   +13 more
wiley   +1 more source